Information on the target
Astorg has signed a definitive agreement to acquire the global microbiology business of Thermo Fisher Scientific, establishing a new independent platform dedicated to diagnostic solutions and laboratory testing. Upon completion of the transaction, Thermo Fisher’s microbiology division will function as a standalone, privately owned entity backed by Astorg. This division is known for its diagnostic consumables and equipment utilized in antimicrobial susceptibility testing and culture media solutions, serving critical applications in clinical, pharmaceutical, and food safety testing.
The microbiology business employs approximately 2,400 professionals and operates 13 manufacturing and research and development facilities across the globe. With a robust client base of around 15,000 organizations managing over 38,000 laboratories in more than 100 countries, the division generates over 95% of its revenues from consumables that are regularly purchased by customers, highlighting its resilience and recurring demand in the market.
Industry overview in the target’s specific country
The microbiology testing industry is experiencing significant growth, driven by increasing complexities in infections, stringent food safety regulations, and heightened quality assurance requirements in pharmaceutical production. As healthcare systems worldwide continue to evolve, the demand for advanced diagnostic solutions is on the rise, positioning the microbiology sector as a critical component of public health and safety.
In the United Kingdom, where the acquisition is taking place, the healthcare sector is robust, supported by a strong regulatory framework and a commitment to innovation. The National Health Service (NHS) and private healthcare providers are increasingly investing in diagnostic technologies to enhance patient outcomes and streamline operations. This trend is further fueled by the growing emphasis on preventive healthcare and early disease detection.
Moreover, the global pandemic has underscored the importance of microbiology testing, leading to increased funding and research initiatives aimed at improving diagnostic capabilities. As a result, companies operating in this space are well-positioned to capitalize on emerging opportunities, particularly in areas such as antimicrobial resistance and food safety testing.
With a solid foundation and a commitment to innovation, the microbiology business is poised to thrive in this dynamic environment, making it an attractive target for investment. A…